CAS No. |
148031-34-9 |
中文名称 |
2-(20-((1H-吲哚-3-基)甲基)-3-氨基甲酰基-11-(4-((二氨基亚甲基)氨基)丁基)-1,9,12,15,18,21-六氧代二十二氢-7H-吡咯并[2,1-g][1,2]二硫杂[5,8,11,14,17,20]六氮杂环三十三碳-17-基)乙酸 |
英文名称 |
2-(20-((1H-indol-3-yl)methyl)-3-carbamoyl-11-(4-((diaminomethylene)amino)butyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2]dithia[5,8,11,14,17,20]hexaazacyclotricosin-17-yl)acetic acid |
别名 |
INTEGRELIN;EPTIFIBATIDE ACETATE;MAP-LYS-GLY-ASP-TRP-PRO-CYS-NH2;Mpr-Harg-Gly-Asp-Trp-Pro-Cys-NH2,( Disulfide Bridge:1-7);Human Eptifibatide;Eptifitide;Mpr-Harg-Gly-Asp-Trp-Pro-Cys-NH2,( Disulfide Bridg on Mpr and Cys);EFTIFIBATIDE |
标准英文名 |
2-(20-((1H-indol-3-yl)methyl)-3-carbamoyl-11-(4-((diaminomethylene)amino)butyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2]dithia[5,8,11,14,17,20]hexaazacyclotricosin-17-yl)acetic acid |
MDL No. |
MFCD05662245 |
分子式 |
C35H49N11O9S2 |
分子量 |
831.98
|
精确分子量 |
831.32
|
SMILES |
NC(=O)C1CSSCCC(=O)NC(CCCCN=C(N)N)C(=O)NCC(=O)NC(CC(=O)O)C(=O)NC(CC2=CNC3=CC=CC=C23)C(=O)N2CCCC2C(=O)N1 |
标准SMILES |
NC(N)=NCCCCC1NC(=O)CCSSCC(NC(=O)C2CCCN2C(=O)C(CC2=CNC3=CC=CC=C23)NC(=O)C(CC(O)=O)NC(=O)CNC1=O)C(N)=O |
用途 |
Eptifibatide is used for the treatment of acute coronary syndrome (including unstable angina and non-ST-segment elevation myocardial infarction), as adjunctive therapy during percutaneous coronary intervention (PCI), and in the management of acute Q-wave myocardial infarction; it reduces the incidence of cardiovascular events, alleviates symptoms of unstable angina, limits the extent of non-Q-wave myocardial infarction, and decreases the occurrence of transmural myocardial infarction. |
InChIKey |
CZKPOZZJODAYPZ-UHFFFAOYSA-N |